Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the second quarter of 2016 and provided a business update. “In the first half of …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Adicet Bio, Inc.announced today a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the first quarter of 2016 and provided a business update. “The year is off to …
It’s an exciting week ahead for pharmaceutical companies Relypsa Inc (NASDAQ:RLYP), GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Exelixis, Inc. (NASDAQ:EXEL), as …
Yesterday, Jennifer asked is Valeant Pharmaceuticals the proverbial canary in the coal mine for the pharma industry? She came to the conclusion that …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the fourth quarter and full year 2015 and provided an update on development programs. “Regeneron had …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the U.S.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively …
